Determining Joint Inventorship: Antibody Paying Attention?
Katherine Tassmer and Todd Garabedian's article, "Determining joint inventorship: antibody paying attention?" was published in The Patent Lawyer Magazine Annual 2021 issue. Their article discusses the tenets of joint inventorship under U.S. law with specific reference to the Dana-Farber decision.
Katherine is a Staff Attorney at Cantor Colburn. She assists with an array of patent and trademark litigation matters, including pharmaceutical litigation under the Hatch-Waxman Act. She also has experience assisting with post-grant proceedings before the United States Patent and Trademark Office Patent Trial and Appeal Board. Katherine is familiar with all stages of intellectual property litigation, including through trial, and is knowledgeable in electronic discovery.
Todd Garabedian, Ph.D., is a Partner and Vice Chair of the Firm's Life Sciences Practice Group. He has extensive experience as an intellectual property attorney in a wide variety of disciplines related to the biological and chemical sciences, including chemistry, biochemistry, organic chemistry, pharmaceuticals, molecular biology, and materials science. Todd began his professional career as a research biochemist at the UCLA School of Medicine and thereafter at Washington State University where he worked in a variety of biological fields mainly centered around protein structure, function, and characterization. Before joining Cantor Colburn, Todd was a Partner at Wiggin and Dana LLP, advising clients in all aspects of patent law in the chemical and life science arts, including patent application preparation, prosecution, counseling, portfolio management, and legal opinions. His experience extends to trademarks, copyrights, trade secrets, and corporate transactions relating to intellectual property assets, including acquisitions, joint ventures, licensing, and other technology transfer transactions.